The supplement classification problem: when is your product a food, a supplement, or a medicine?

One of the most consequential decisions in getting a health product to market is one that many brands don't realise they're making: whether their product is classified as a food, a health supplement, or a medicine. Get it wrong, and you're in the wrong regulatory pathway, one that can add years and costs you didn't budget for.

The problem is that the answer isn't consistent across markets. A product that's clearly a food supplement in Australia may be classified as a medicine in Germany. A functional beverage that's a food in Singapore may require pharmaceutical registration in Indonesia. A protein powder that's a food in the US may be a health supplement in Malaysia.

Why classification matters so much

Classification determines which regulatory authority has jurisdiction, what the registration or notification pathway is, what claims you can make, what ingredient limits apply, what labelling format is required, and how long market entry takes and what it costs. A product incorrectly classified as a food when it should be a supplement faces rejection at the notification stage. A product incorrectly positioned as a supplement when it qualifies as a medicine faces enforcement action, or simply cannot make the claims the brand is relying on commercially.

How major markets classify health products

Australia

The TGA/FSANZ split is based on purpose and presentation. Products with therapeutic claims or containing therapeutic ingredients above certain thresholds go TGA. Products in food format without therapeutic claims go FSANZ. The classification is product and claim-specific, there's no single rule that covers all scenarios.

Singapore

HSA regulates health supplements (non-food format, not intended to treat disease). SFA regulates food including functional food. The determining factor is primarily format and primary purpose. Capsule: supplement. Drink: probably food. But a drink with high-dose botanicals making functional claims: potentially supplement territory.

Indonesia

BPOM has three relevant categories: food (pangan), health supplement (suplemen kesehatan), and traditional medicine (obat tradisional). The distinction between suplemen kesehatan and obat tradisional has significant implications: different permitted ingredients, different claims, different registration pathways.

Malaysia

NPRA's natural health products (NHP) category covers most supplements. But some products with stronger therapeutic claims or potent active ingredients may fall under pharmaceutical classification, requiring a different pathway and longer registration timeline.

European Union

The EU distinguishes between food supplements (Directive 2002/46/EC) and medicinal products. Key factors: the concentration of active substances, whether the product presents a physiological effect in normal use, and how it's presented to consumers. A product that looks like a supplement but makes claims typical of medicines may be reclassified as a medicinal product by national authorities.

United States

Dietary supplements under DSHEA are defined as products intended to supplement the diet. The drug/supplement boundary is claim-based: if a product claims to treat, diagnose, cure, or prevent disease, it's a drug. Structure/function claims are allowed for supplements with the appropriate disclaimer.

The grey zones that catch brands out

High-dose vitamins and minerals. Products with vitamins or minerals at therapeutic doses may cross from food supplement to medicine territory in some European markets, even if the same doses are freely sold as supplements in Australia or the US.

Botanical extracts with pharmacological activity. Ginkgo biloba, St John's Wort, valerian: these are in the permitted lists for supplements in many markets, but at higher concentrations or with specific claims, they may tip into medicine classification.

Products with multiple active ingredients. A combination product may be classified as a supplement based on its primary ingredient but face different rules for a secondary ingredient that, on its own, would require pharmaceutical registration.

Format shifts. The same formulation in capsule vs liquid form can face different classification in the same market.

What to do

For any product entering a new market, classification should be determined before the regulatory pathway is chosen, not during it. Answer these questions first: What category does this product type typically fall into in this market? Do any ingredients create classification risk at their formulation levels? Do the intended claims push the product toward a higher-risk category? Has the classification been confirmed against current regulations, not assumptions from similar products in other markets?

Taama's regulatory classification module gives supplement and food brands a definitive pathway verdict for each target market. See what we cover